Cargando…
Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis
Prepubertal exposure to a pharmacological dose (500 mg kg(−1)) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic–pituitary–gonadal axis, making it unsuitab...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363126/ https://www.ncbi.nlm.nih.gov/pubmed/10468283 http://dx.doi.org/10.1038/sj.bjc.6690584 |
_version_ | 1782153626742947840 |
---|---|
author | Hilakivi-Clarke, L Onojafe, I Raygada, M Cho, E Skaar, T Russo, I Clarke, R |
author_facet | Hilakivi-Clarke, L Onojafe, I Raygada, M Cho, E Skaar, T Russo, I Clarke, R |
author_sort | Hilakivi-Clarke, L |
collection | PubMed |
description | Prepubertal exposure to a pharmacological dose (500 mg kg(−1)) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic–pituitary–gonadal axis, making it unsuitable for breast cancer prevention. We studied whether prepubertal exposure to genistein at a total body dose broadly comparable to the level typical of Oriental countries, approximately 1 mg kg(−1) body weight, affects mammary tumorigenesis. We also studied whether prepubertal exposure to zearalenone, a major source for phyto-oestrogens in the USA, influences breast cancer risk. Prepubertal rats were treated between postnatal days 7 and 20, with 20 μg (~ 1 mg kg(−1) body weight) of either genistein or zearalenone. Zearalenone exposure significantly reduced both the incidence and multiplicity of mammary tumours induced by 7,12-dimethylbenz(a)anthracene (DMBA). Genistein exposure significantly reduced tumour multiplicity, but not tumour incidence, when compared with vehicle-treated animals. Furthermore, 60% of the tumours in the genistein group were not malignant, while all the tumours analysed for histopathology in the vehicle and zearalenone groups were adenocarcinomas. A higher number of differentiated alveolar buds, and lower number of terminal ducts, were present in the DMBA-treated mammary glands of the phyto-oestrogen exposed rats. The concentration of oestrogen receptor (ER) binding sites after the DMBA treatment was low in the mammary glands of all groups but a significantly higher proportion of the glands in the zearalenone exposed rats were ER-positive (i.e. ER levels ≥ 5 fmol mg(−1) protein) than the glands of the vehicle controls. Our data suggest that a prepubertal exposure to a low dose of either zearalenone or genistein may protect the mammary gland from carcinogen-induced malignant transformation, possibly by increasing differentiation of the mammary epithelial tree. © 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2363126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23631262009-09-10 Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis Hilakivi-Clarke, L Onojafe, I Raygada, M Cho, E Skaar, T Russo, I Clarke, R Br J Cancer Regular Article Prepubertal exposure to a pharmacological dose (500 mg kg(−1)) of the phyto-oestrogen genistein can reduce the incidence and multiplicity of carcinogen-induced mammary tumours in rats. However, such an exposure also disrupts the function of the hypothalamic–pituitary–gonadal axis, making it unsuitable for breast cancer prevention. We studied whether prepubertal exposure to genistein at a total body dose broadly comparable to the level typical of Oriental countries, approximately 1 mg kg(−1) body weight, affects mammary tumorigenesis. We also studied whether prepubertal exposure to zearalenone, a major source for phyto-oestrogens in the USA, influences breast cancer risk. Prepubertal rats were treated between postnatal days 7 and 20, with 20 μg (~ 1 mg kg(−1) body weight) of either genistein or zearalenone. Zearalenone exposure significantly reduced both the incidence and multiplicity of mammary tumours induced by 7,12-dimethylbenz(a)anthracene (DMBA). Genistein exposure significantly reduced tumour multiplicity, but not tumour incidence, when compared with vehicle-treated animals. Furthermore, 60% of the tumours in the genistein group were not malignant, while all the tumours analysed for histopathology in the vehicle and zearalenone groups were adenocarcinomas. A higher number of differentiated alveolar buds, and lower number of terminal ducts, were present in the DMBA-treated mammary glands of the phyto-oestrogen exposed rats. The concentration of oestrogen receptor (ER) binding sites after the DMBA treatment was low in the mammary glands of all groups but a significantly higher proportion of the glands in the zearalenone exposed rats were ER-positive (i.e. ER levels ≥ 5 fmol mg(−1) protein) than the glands of the vehicle controls. Our data suggest that a prepubertal exposure to a low dose of either zearalenone or genistein may protect the mammary gland from carcinogen-induced malignant transformation, possibly by increasing differentiation of the mammary epithelial tree. © 1999 Cancer Research Campaign Nature Publishing Group 1999-08 /pmc/articles/PMC2363126/ /pubmed/10468283 http://dx.doi.org/10.1038/sj.bjc.6690584 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Hilakivi-Clarke, L Onojafe, I Raygada, M Cho, E Skaar, T Russo, I Clarke, R Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis |
title | Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis |
title_full | Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis |
title_fullStr | Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis |
title_full_unstemmed | Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis |
title_short | Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis |
title_sort | prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363126/ https://www.ncbi.nlm.nih.gov/pubmed/10468283 http://dx.doi.org/10.1038/sj.bjc.6690584 |
work_keys_str_mv | AT hilakiviclarkel prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis AT onojafei prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis AT raygadam prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis AT choe prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis AT skaart prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis AT russoi prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis AT clarker prepubertalexposuretozearalenoneorgenisteinreducesmammarytumorigenesis |